Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study
Crossref DOI link: https://doi.org/10.1007/s10067-017-3686-6
Published Online: 2017-06-07
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schmitz, E. M. H.
Benoy - De Keuster, S.
Meier, A. J. L.
Scharnhorst, V.
Traksel, R. A. M.
Broeren, M. A. C.
Derijks, L. J. J. http://orcid.org/0000-0002-6038-9295
License valid from 2017-06-07